Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design
MA Lyons - CPT: Pharmacometrics & Systems Pharmacology, 2021 - Wiley Online Library
Clinical development of combination chemotherapies for tuberculosis (TB) is complicated by
partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance …
partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance …
[HTML][HTML] Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design
MA Lyons - CPT: Pharmacometrics & Systems Pharmacology, 2021 - ncbi.nlm.nih.gov
Clinical development of combination chemotherapies for tuberculosis (TB) is complicated by
partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance …
partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance …
Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design.
MA Lyons - CPT: Pharmacometrics & Systems …, 2021 - search.ebscohost.com
Clinical development of combination chemotherapies for tuberculosis (TB) is complicated by
partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance …
partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance …
Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design
MA Lyons - CPT: Pharmacometrics & Systems Pharmacology, 2021 - search.proquest.com
Clinical development of combination chemotherapies for tuberculosis (TB) is complicated by
partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance …
partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance …
Pretomanid dose selection for pulmonary tuberculosis: An application of multi-objective optimization to dosage regimen design
MA Lyons - CPT: pharmacometrics & systems …, 2021 - pubmed.ncbi.nlm.nih.gov
Clinical development of combination chemotherapies for tuberculosis (TB) is complicated by
partial or restricted phase II dose-finding. Barriers include a propensity for drug resistance …
partial or restricted phase II dose-finding. Barriers include a propensity for drug resistance …
Pretomanid dose selection for pulmonary tuberculosis: An application of multi-objective optimization to dosage regimen design.
MA Lyons - CPT: Pharmacometrics & Systems Pharmacology, 2021 - europepmc.org
Clinical development of combination chemotherapies for tuberculosis (TB) is complicated by
partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance …
partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance …